-
Mashup Score: 4
Application supported by statistically significant and clinically meaningful progression-free and overall survival data from RUBY trial
Source: us.gsk.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 1
End-of-trial data show 79.7% efficacy in participants aged 50 years and over, six to 11 years after vaccination
Source: us.gsk.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 1GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA | GSK US - 19 day(s) ago
Submission based on results from pivotal phase III trial showing all primary endpoints met
Source: us.gsk.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 1GSK announces cap of $35 per month on U.S. patient out-of-pocket costs for its entire portfolio of asthma and COPD inhalers | GSK US - 1 month(s) ago
GSK is taking this action as part of its longstanding commitment to improving access to respiratory medicines in the U.S.
Source: us.gsk.comCategories: General Medicine News, Allergy-ImmunologyTweet
-
Mashup Score: 5GSK announces cap of $35 per month on U.S. patient out-of-pocket costs for its entire portfolio of asthma and COPD inhalers | GSK US - 2 month(s) ago
GSK is taking this action as part of its longstanding commitment to improving access to respiratory medicines in the U.S.
Source: us.gsk.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 2
Only immuno-oncology combination to show statistically significant and clinically meaningful overall survival in overall population.
Source: us.gsk.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 1Creating a Culture of Holistic Care in Lupus | GSK US - 2 month(s) ago
Lupus is a disease that flares and damages vital organs, GSK aims to improve lives through holistic care and a culture of health.
Source: us.gsk.comCategories: General Medicine News, PayerTweet-
Delayed #lupus diagnosis can damage organs like the kidneys. Social factors like workplace and lifestyle can be barriers to early diagnosis for diseases. Learn why social drivers of health must be considered when making healthcare decisions #WorldKidneyDay https://t.co/tJu9cJRHE6 https://t.co/c4G4Ykg0re
-
-
Mashup Score: 1Women in science: Nicole Godfrey | GSK US - 2 month(s) ago
Go Behind the science and read our Women in Science series. Meet Nicole Godfrey, Medicinal Chemist.
Source: us.gsk.comCategories: General Medicine News, PayerTweet-
We are incredibly proud to acknowledge the brilliant #womeninSTEM across our company. We embolden and learn from each other, and always encourage the next generation of women to follow in our footsteps. Read Nicole's story: https://t.co/sumFVuM2hc #InternationalWomensDay #IWD2024 https://t.co/9VCzxsWfH6
-
-
Mashup Score: 1GSK doubles COiMMUNITY grant funding, launches patient resources, as adult vaccination rates begin to show promising rise | GSK US - 2 month(s) ago
We are committing up to $2 million in 2024 to support adult immunization and health equity programs.
Source: us.gsk.comCategories: General Medicine News, PayerTweet-
As part of our goal to achieve higher adult vaccination rates and #HealthEquity in the US, we are announcing the second year of our COiMMUNITY Initiative, with new patient resources and additional funding to support #nonprofits and community-based groups: https://t.co/C0qG7VOJRl https://t.co/pGrMQkn1Hd
-
-
Mashup Score: 0Diversity, equity and inclusion | GSK US - 2 month(s) ago
Our approach, which is focused on our People, our Business and our Communities, starts inside our company
Source: us.gsk.comCategories: General Medicine News, PayerTweet
#News for #Investors and #Media: Our application for a potential expanded indication for our immuno-oncology therapy has been accepted by the @US_FDA with Priority Review status. Learn more here: https://t.co/wNaP8epqS5 https://t.co/IgkFV5Zrlc